Initiation of generic imatinib may improve medication adherence for patients with chronic
活着电影观后感
myeloid leukemia
菜心怎么做好吃
期刊名称： Pharmacoepidemiology and Drug Safety
作者： Ashley L. Cole,Shelley A. Jazowski,Stacie B. Dutzina
布满荆棘
年份： 2019年
生蚝保存
期号： 第14期
关键词： adherence;cancer;imatinib;persistence;pharmacoepidemiology
摘要：Purpo To compare adherence to tyrosine kina inhibitors (TKIs) between patients with chronic myeloid leukemia (CML) who initiated branded or generic imatinib. Methods We ud MarketScan commercial claims data (January 2011‐June 2018) to identify patients with CML who newly initiated branded imatinib before 1 August 2015 or generic imatinib on or after 2 February 2016,
葡萄的英语怎么写and were continuously enrolled in health plans for 6 months before through 6 months following their initial fill. After inver probability of treatment weighting, we compared adherence (proportion of days covered [PDC]) and persistence (no gaps ≥30 and ≥60 concutive days in therapy) to TKI therapy. Results Patients initiating generic imatinib consistently had higher average PDC per month and over the 6‐month follow‐up period than initiators 星火英语听力>运动鞋排行榜
爱国题材手抄报内容由中国教育图书进出口有限公司引进
